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A B S T R A C T
Drug eﬄux transporters, in particular P-glycoprotein (Pgp), limit the success of chemotherapy. We previously
found that synthetic doxorubicin conjugated with nitric oxide (NO)-releasing group overcomes resistance by
inducing a NO-mediated inhibition of Pgp. Here we produced the ﬁrst liposomal formulations of this nitrooxy-
doxorubicin decorated with folic acid (FA), termed LNDF, in order to improve their active targeting against Pgp-
expressing tumors. Folate was inserted onto liposomes surface using two diﬀerent methods and the formulations
were compared with respect to their technological features and in vitro behavior. By analyzing human and
murine breast cancer cells with diﬀerent expression of FA receptor (FAR) and Pgp, we demonstrated that LNDF
are internalized in a FAR-dependent manner and achieve maximal anti-tumor eﬃcacy against FAR-positive/Pgp-
positive cells. Upon uptake of LNDF, nitrooxy-doxorubicin was delivered within nucleus, where it induced cell
cycle arrest and DNA damages, and mitochondria, where it impaired the mitochondrial energy metabolism and
triggered mitochondria-dependent apoptosis. LNDF reduced the growth of FAR-positive/Pgp-positive tumors
and prevented tumor formation in mice, whereas doxorubicin and Caelyx® failed. LNDF cardiotoxicity was
comparable to Caelyx®. The sensitivity to LNDF was maintained in tumors exposed to repeated cycles of the drug
and in cells derived from the exposed tumors, excluding the onset of secondary resistance.
By combining an innovative multitarget cargo drug, conceived to achieve high eﬃcacy against Pgp-expres-
sing cells, and appropriate strategies of liposome formulation and decoration, we produced a therapeutic tool
that may represent a signiﬁcant advancement in the treatment of FAR-positive/Pgp-positive tumors.
1. Introduction
Multidrug resistance (MDR) is a multiple resistance towards dif-
ferent chemotherapeutic drugs, unrelated for structures and pharma-
codynamic properties. One of the main mechanisms of MDR is the high
expression on cell surface of ATP binding cassette (ABC) transporters,
such as P-glycoprotein (Pgp), MDR-related proteins (MRPs), breast
cancer resistance protein (BCRP), lung resistance protein (LRP). For the
broad spectrum of substrates, including anthracyclines like doxorubicin
(Dox), taxanes, vinca alkaloids, epipodophyllotoxins, topotecan,
methotrexate, and targeted-therapies such as imatinib, dasatinib,
lapatinib, geﬁtinib, sorafenib, and erlotinib, Pgp is one of the main
determinant of MDR [1,2].
Natural and synthetic inhibitors of ABC transporters have been
tested to reverse MDR phenotype: although successful in vitro, they
often failed in vivo for the low speciﬁcity, the side-eﬀects induced and
the drug-drug interactions that produced unexpected toxicity [3]. Re-
cently, small molecules endorsed with speciﬁc cytotoxicity against ABC
transporter-expressing cells have been widely studied as a new ap-
proach to overcome MDR. However, the poor mechanistic knowledge at
the basis of their selective cytotoxicity for MDR cells, an event known as
“collateral sensitivity” [4], has limited the application of these agents to
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in vitro models. Gene-silencing of ABC transporters, co-delivery of ABC-
transporter silencers and chemotherapeutic drug [5], inhibition of
transcription factors that up-regulate these proteins [6] or of surface
proteins adjuvanting ABC transporters activity [7] have been also ex-
perimented in vitro and in preclinical models, but the translation po-
tential of these approaches to oncological patients is far.
We recently developed multi-target synthetic derivatives of Dox,
conjugated with substructures releasing nitric oxide (NO); by nitrating
critical tyrosines on ABC transporters, NO impairs the catalytic activity
of the pumps, allowing the increased intracellular retention and cyto-
toxicity of Dox [8]. Besides inhibiting their own eﬄux [9,10], some of
these NO-releasing doxorubicins - like the nitrooxy-Dox derivative (ND)
- revealed pharmacodynamic properties completely diﬀerent from
parental Dox [11,12].
Liposomal formulations of ND (LND) were eﬀective in vitro against
human breast and ovary cancer drug-resistant cells, showing a superior
eﬃcacy to Caelyx® [13], the Dox liposomal formulation used in patients
bearing these type of tumors [14].
To further reﬁne the tumor speciﬁcity and eﬃcacy of LND, in this
work we produced and validated LND formulations decorated with folic
acid (FA), termed LNDF. Since FA is not-immunogenic and binds with
high speciﬁcity to the FA receptor (FAR), a protein overexpressed in
many tumor cells respect to not transformed cells [15], it is an eﬀective
small molecule for active targeting of liposomes and nanoparticles. To
validate the eﬃcacy of our formulations, we focused on drug-resistant
Pgp-positive breast tumors, that include up to 56% tumors positive for
FAR [16]. A part the reduced cardiotoxicity, Caelyx® did not oﬀer a
signiﬁcant advance over Dox in the treatment of breast tumors [14],
leaving the ﬁeld open to the research of more eﬀective anthracycline-
based treatments. This is of particular importance for triple negative
breast cancers, where anthracycline- or taxane-based monotherapy re-
gimes are the ﬁrst-line treatment [17], but the rate of success of
pharmacological therapy is lower compared to other breast cancer
types [18].
The aim of the present work was to produce, characterize, and va-
lidate LNDF as an eﬀective and safe tool against Pgp-positive che-
moresistant breast cancers.
2. Materials and methods
2.1. Chemicals
All the phospholipids were provided by Avanti Polar-Lipids dis-
tributed by Spectra 2000 (Rome, Italy). Folate-polyethylene glycol-
distearoylphosphatidylethanolamine (FA-PEG-DSPE; PEG mean mole-
cular weight, 3400 Da) was obtained from NANOCS distributed by DBA
Italia (Segrate, Milano, Italy). Cholesterol, Dox and all the other che-
micals were obtained from Sigma Chemical Co. (St. Louis Mo). All the
solvents used were of analytical grade, purchased from Carlo Erba
Reagenti (Milan, Italy). Fetal bovine serum (FBS), fetal calf serum (FCS)
and culture medium were supplied by Invitrogen Life Technologies
(Carlsbad, CA); plasticware for cell cultures was from Falcon (Bectison
Dickinson, Franklin Lakes, NJ). Electrophoresis reagents were obtained
from Bio-Rad Laboratories (Hercules, CA); the protein content of cell
monolayers and lysates was assessed with the BCA kit from Sigma
Chemical Co. The synthesis of nitrooxy-doxorubicin was performed as
described previously [9].
2.2. Preparation of liposomes
Liposomes containing ND (LND) were prepared as previously de-
scribed [13]. Folate-targeted liposomes (LNDFm and LNDFpi) were
prepared with two diﬀerent methods. LNDFm were prepared by adding
the FA-PEG-DSPE conjugate to the other phospholipids during lipid ﬁlm
preparation. Brieﬂy, chloroform or methanol solution of 1,2-distearoyl-
sn-glycero-3-phosphocholine (DSPC), cholesterol (Chol), 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-
2000] (mPEG-DSPE, ammonium salt) and FA-PEG-DSPE, at a molar
ratio of 75.7:18.9:2.7:2.7 and containing ND (11% ratio mol drug/mol
lipid) were evaporated and the resulting lipid ﬁlm was dried under
vacuum overnight. The thin ﬁlm was then hydrated with a 20 mM 4-(2-
hydroxyethyl)piperazine-1-ethanesulforic acid (HEPES) buﬀer (pH 7.4)
and the suspension was vortex mixed for 10 min and bath sonicated.
The formulations were then sequentially extruded (Extruder, Lipex,
Vancouver, Canada) through 400 and then 200 nm polycarbonate
membrane (Costar, Corning Incorporated, NY) at a set temperature of
5 °C above the phase transition temperature of the lipid mixture. Li-
posomal preparations were puriﬁed from non-encapsulated ND through
chromatography on Sepharose CL-4B columns, eluting with HEPES
buﬀer at room temperature.
LNDFpi were prepared by adding the FA-PEG-DSPE conjugate by
post insertion method [19] into pre-formed liposomes composed by
DSPC/Chol/mPEG-DSPE in a molar ratio of 75.7:18.9:5.4 and ND (11%
ratio mol drug/mol lipid) prepared as previously described. Liposomes
were incubated with a concentrated micellar FA-PEG-DSPE conjugate
solution at 60 °C for 2 h, at a ligand molar ratio of 3.2% relative to total
phospholipids. Then, the mixture was cooled and liposomes were pur-
iﬁed from excess of FA-PEG-DSPE conjugate and ND through chroma-
tography on Sepharose CL-4B column, eluting with HEPES buﬀer.
2.3. Liposome characterization
The mean particle size and polydispersity index of the liposomes
were determined at 20 °C by Quasi-elastic light scattering (QELS) using
a nanosizer Coulter® N4MD (Coulter Electronics, Inc., Hialeah, FL). The
selected angle was 90° and the measurement was taken after dilution of
the liposome suspensions in MilliQ® water. Each measurement was
carried out in triplicate. The surface charge of liposomes was evaluated
by zeta potential measurements after dilution of the suspensions in
10 mM KCl using a Zetasizer (Zeta Potential Analyzer Ver. 2.17,
Brookhaven Inst. Corp., Holtsville, NY). Phospholipid phosphorous was
assessed in each liposome preparation by phosphate assay after de-
struction with perchloric acid [20].
The amount of ND incorporated in liposomes was determined by
reverse phase (RP)-HPLC as previously reported [13].
The total amount of folate and the number of folate molecules per
liposome were determined spectroscopically at 285 nm by comparison
to a standard curve of FA and the known lipid concentration [21].
The colloidal stability of the suspensions was evaluated by mea-
suring the mean size of the formulations over a storage period of
28 days at 4 °C; the stability was also tested in HEPES buﬀer and FCS at
37 °C for 48 h.
To evaluate ND release in FCS the formulations were diluted 1:2.5
with FCS and incubated at 37 °C for various periods of time; drug
leakage was determined submitting 200 μL of liposomes to puriﬁcation
through chromatography on Sepharose CL-4B columns, eluting with
HEPES buﬀer. Then, the drug and lipid content was measured in the
collected liposomal fractions and compared with initial values. For
comparison, a drug leakage study was also performed in HEPES buﬀer
at 37 °C.
2.4. Cell lines
Human non transformed breast epithelial MCF10A cells, human
breast cancer MCF7, SKBR3, T74D, MDA-MB-231 cells, human osteo-
sarcoma U-2OS cells, murine mammary cancer JC cells were purchased
from ATCC (Manassas, VA). Murine mammary cancer TUBO cells were
a kind gift of Prof. Federica Cavallo, Department of Molecular
Biotechnology and Health Sciences, University of Turin, Italy. Cells
were maintained in mediums supplemented with 10% v/v fetal bovine
serum, 1% v/v penicillin-streptomycin, 1% v/v L-glutamine.
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2.5. Immunoblotting
Cells were lysed in MLB buﬀer (125 mM Tris-HCl, 750 mM NaCl, 1%
v/v NP40, 10% v/v glycerol, 50 mM MgCl2, 5 mM EDTA, 25 mM NaF,
1 mM NaVO4, 10 μg/mL leupeptin, 10 μg/mL pepstatin, 10 μg/mL
aprotinin, 1 mM phenylmethylsulfonyl ﬂuoride, pH 7.5), sonicated and
centrifuged at 13,000 ×g for 10 min at 4 °C. 20 μg of proteins from cell
lysates or tumor homogenates were subjected to Western blotting and
probed with the following antibodies: anti-FAR antibody (Abcam,
Cambridge, UK); anti-Pgp (BD Biosciences, San Josè, CA), anti-MRP1
(Abcam, Cambridge, UK), anti-tubulin (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA). The proteins were detected by enhanced chemilumi-
nescence (Bio-Rad Laboratories).
2.6. Flow cytometry
Cells were washed with PBS, detached with Cell Dissociation
Solution (Sigma) and re-suspended in culture medium containing 5% v/
v FBS. Samples were washed with 0.25% w/v PBS-bovine serum al-
bumin (BSA), incubated with the primary antibody for anti-FAR for
45 min at 4 °C, then washed twice and incubated with the secondary
ﬂuorescein isothiocyanate-conjugated antibody for 30 min at 4 °C. After
washing and ﬁxation in paraformaldehyde 2 w/v %, the surface amount
of FAR was detected on 100,000 cells by a FACSCalibur system (Becton
Dickinson), using the Cell Quest software (Becton Dickinson). Control
experiments included incubation of cells with non-immune isotypic
antibody, followed by secondary antibody.
2.7. Cellular uptake of doxorubicins
Cells were incubated with Dox, ND or respective formulations for 0,
1, 3, 6, and 24 h. The amount of compounds in cell lysates was mea-
sured spectroﬂuorimetrically, as described in [8] using a Synergy HT
Multi-Detection Microplate Reader (Bio-Tek Instruments, Winooski,
VT). Excitation and emission wavelengths were 475 and 553 nm, re-
spectively. A blank was prepared in the absence of cells for each set of
experiments, and its ﬂuorescence was subtracted from that measured in
the presence of cells. In competition assays, cells were incubated 6 h
with 5 μM folate-targeted liposomes, in the presence of an excess of free
FA (50 μM) or a saturating amount of anti-FAR antibody (100 μg/mL).
The amount of intracellular compounds was measured as reported
above; ﬂuorescence was converted to nmol Dox/mg cell or tissue pro-
teins using a calibration curve prepared previously. The amount of
doxorubicins in nuclear and mitochondrial extracts (see below) was
measured by HPLC, as reported in [11]. Results were expressed as
nmoles doxorubicins/mg cell proteins.
2.8. Nitrite production
Nitrite production was measured by adding 0.15 mL of cell culture
medium to 0.15 mL of Griess reagent in a 96-well plate, and after a
10 min incubation at 37 °C in the dark, the absorbance was detected at
540 nm with a Packard EL340 microplate reader (Bio-Tek Instruments).
A blank was prepared for each experiment in the absence of cells, and
its absorbance was subtracted from the one obtained in the presence of
cells. Nitrite concentration was expressed as nmoles/mg cell proteins.
2.9. Extracellular lactate dehydrogenase (LDH) activity
To verify the cytotoxic eﬀect of compounds, the extracellular
medium was centrifuged at 12,000 ×g for 15 min to pellet cellular
debris, whereas cells were washed with fresh medium, detached with
trypsin/EDTA, re-suspended in 0.2 mL of 82.3 mM triethanolamine
phosphate-HCl (pH 7.6) and sonicated on ice with two 10 s bursts. LDH
activity was measured in the extracellular medium and in the cell ly-
sate, as reported [8]. The reaction was followed for 6 min, measuring
absorbance at 340 nm with Packard EL340 microplate reader (Bio-Tek
Instruments) and was linear throughout the time of measurement. Both
intracellular and extracellular enzyme activity was expressed in μmoles
NADH oxidized/min/dish, then extracellular LDH activity was calcu-
lated as percentage of the total LDH activity in the dish.
2.10. Cell viability
Cell viability was measured by the neutral red staining method, as
previously reported [22]. The absorbance at 540 nm was read using a
Synergy HT Multi-Detection Microplate Reader (Bio-Tek Instruments).
The absorbance of untreated cells was considered as 100% viability; the
results were expressed as percentage of viable cells versus untreated
cells.
2.11. Fluorescence and confocal microscope analysis
For ﬂuorescence microscopy analysis, 0.5 × 105 cells were grown
on sterile glass coverslips, then rinsed with PBS, ﬁxed with 4% w/v
paraformaldehyde for 15 min, washed three times with PBS and in-
cubated with 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI,
diluted 1: 20,000) for 3 min at room temperature in the dark.
Fluorescently labelled cells were washed three times with PBS and once
with water, then the slides were mounted with 4 μL of Gel Mount
Aqueous Mounting and examined using a Leica DC100 microscope
(Leica Microsystems, Wetzlar, Germany) with a 63 x oil immersion
objective and 10 × ocular lens. In confocal microscopy analysis for
compounds intracellular localization, cells were previously transfected
with expression vectors encoding for the GFP-fused-leader sequence of
E1-α-pyruvate dehydrogenase to label mitochondria for 18 h (Cell Light
BacMan 2.0, Invitrogen), then incubated for 6 h with the compounds
and prepared as reported above. Image acquisition was performed with
a Leica TCS SP2 AOBS confocal laser-scanning microscope with a
63 × oil immersion objective and 10 × ocular lens. For each experi-
mental point, a minimum of 5 microscopic ﬁelds were examined.
Imaging quantiﬁcation was performed with ImageJ software (https://
imagej.nih.gov/i). Fluorescence intensity in cells treated with Dox was
set as 1 unit. Results were expressed as relative ﬂuorescence units
(RFU).
2.12. Cytosol-nucleus separation
Cells were mechanically scraped in PBS, washed and re-suspended
in lysis buﬀer A (15 mM KCl, 10 mM Hepes, 2 mM MgCl2, 0.1 mM
EDTA, 1 mM phenylmethylsulfonyl ﬂuoride (PMSF), 1 mM DTT, 10 μg/
mL aprotinin, 2 μg/mL leupeptin, 0.1% v/v NP-40, pH 7.6). This sus-
pension was incubated for 10 min on ice with occasional vortexing and
centrifuged at 13,000 ×g for 30 s to pellet nuclei. The supernatant
(cytosolic fraction) was transferred into a new series of tubes. Nuclei
were rinsed with 0.2 mL of wash buﬀer B (2 M KCl, 25 mM HEPES,
0.1 mM EDTA, 1 mM PMSF, 1 mM DTT, 10 μg/mL aprotinin, 2 μg/mL
leupeptin, pH 7.6) and incubated at 4 °C for 20 min. Then an equal
volume of buﬀer C (25 mM HEPES, 0.1 mM EDTA, 20% v/v glycerol,
pH 7.6) was added, the mix was centrifuged at 20,000 ×g for 15 min
and the supernatant (nuclear fraction) was collected. The protein con-
tent was measured in both cytosolic and nuclear extracts; samples were
stored at−80 °C until use. Doxorubicins content in the nuclear extracts
was measured as described above.
2.13. Cell cycle analysis
Cells were washed twice with fresh PBS, incubated in 0.5 mL ice-
cold ethanol 70% v/v for 15 min, then centrifuged at 1200 ×g for
5 min at 4 °C and rinsed with 0.3 mL of citrate buﬀer (50 mM Na2HPO4,
25 mM sodium citrate, 1% v/v Triton X-100), containing 10 μg/mL
propidium iodide and 1 mg/mL RNAse (from bovine pancreas). After a
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15 min incubation in the dark, the intracellular ﬂuorescence was de-
tected by a FACSCalibur ﬂow cytometer. For each analysis, 10,000
events were collected and analyzed by the Cell QuestPro software
(Becton Dickinson).
2.14. Comet assay
The Single Cell Gel Electrophoresis assay (Comet assay), performed
as reported previously [23], was used to measure the doxorubicin-in-
duced DNA damage, as index of genotoxicity. Images were quantiﬁed
by the CometScore software (TriTek Corp., Sumerduck, VA).
2.15. Mitochondria isolation
To isolate mitochondrial fractions, cells were washed twice in ice-
cold PBS, then lysed in 0.5 mL mitochondria lysis buﬀer (50 mM Tris,
100 mM KCl, 5 mN MgCl2, 1.8 mM ATP, 1 mM EDTA, pH 7.2), sup-
plemented with protease inhibitor cocktail III (Calbiochem), 1 mM
PMSF and 250 mM NaF. Samples were clariﬁed by centrifuging at
650 ×g for 3 min at 4 °C; the supernatant was collected and centrifuged
at 13,000 ×g for 5 min at 4 °C. This supernatant (cytosolic extract) was
transferred to a new series of tubes, and stored at−80 °C after protein
quantiﬁcation. The pellet containing mitochondria was washed once
with lysis buﬀer and re-suspended in 0.25 mL mitochondria resuspen-
sion buﬀer (250 mM sucrose, 15 mM K2HPO4, 2 mM MgCl2, 0.5 mM
EDTA). A 50 μL aliquot was sonicated and used for the measurement of
protein content or Western blotting. To conﬁrm the presence of mi-
tochondrial proteins in the extracts, 10 μg of each sonicated sample
were subjected to SDS-PAGE and probed with an anti-VDAC/porin
antibody (data not shown). Doxorubicins content in the mitochondrial
extracts was measured as described above.
2.16. Reactive nitrogen species (RNS) and reactive oxygen species (ROS)
measurement
RNS were measured in the mitochondrial extracts by quantifying
the amount of nitrotyrosines, an index of peroxynitrite production, with
the Nitrotyrosine ELISA kit (Hycult Biotechnology, The Netherlands)
following the manufacturer's instructions. The absorbance was read
with a Packard EL340 microplate reader (Bio-Tek Instruments) and
converted into pmol/mg mitochondrial proteins according to the ti-
tration curve. To measure intramitochondrial ROS, 100 μg unsonicated
mitochondria were re-suspended in 0.5 mL PBS, incubated for 30 min at
37 °C with 5 μM of the ﬂuorescent probe 5-(and-6)-chloromethyl-2′,7′-
dichlorodihydro-ﬂuorescein diacetate-acetoxymethyl ester (DCFDA-
AM), centrifuged at 13,000 ×g at 37 °C and re-suspended in 0.5 mL
PBS. The ﬂuorescence of each sample, considered an index of ROS le-
vels, was read at 492 nm (λ excitation) and 517 nm (λ emission). The
results were expressed as nmoles/mg cell mitochondrial proteins.
2.17. Tricarboxylic acid cycle (TCA) measurement
The glucose ﬂux through tricarboxylic acid (TCA) cycle was mea-
sured by radiolabeling cells with 2 μCi/mL [6-14C]-glucose (55 mCi/
mmol; PerkinElmer). Cell suspensions were incubated for 1 h in a closed
experimental system to trap the 14CO2 developed from[14C]-glucose,
and the reaction was stopped by injecting 0.5 mL of 0.8 N HClO4. The
amount of glucose transformed into CO2 through the TCA cycle was
calculated as described [24] and expressed as pmoles CO2/h/mg cell
proteins.
2.18. Mitochondrial respiratory chain assays
Mitochondria were extracted as described above. The electron ﬂux
from Complex I to Complex III was measured on 10 μg of non-sonicated
mitochondrial extracts, as previously reported [25]. Each sample was
incubated in the absence or presence of the Complex I inhibitor rote-
none (50 μM), to measure the ubiquinone-independent and the ubi-
quinone-dependent electron ﬂux, respectively. The reaction was fol-
lowed for 5 min, using a Packard EL340 microplate reader (Bio-Tek
Instruments). Results were expressed as nmoles reduced cytochrome c/
min/mg mitochondrial proteins.
2.19. ATP measurement
The amount of ATP was measured on 20 μg of mitochondrial ex-
tracts or on 100 μL of cell supernatants with the ATP Bioluminescent
Assay Kit (FL-AA, Sigma Aldrich Co.), using a Synergy HT Multi-Mode
Microplate Reader (Bio-Tek Instruments). ATP was quantiﬁed as arbi-
trary light units; data were converted into nmoles/mg mitochondrial
proteins, using a calibration curve previously set.
2.20. Mitochondrial damage
1 × 106 cells re-suspended in 0.5 mL PBS were incubated for
30 min at 37 °C with the ﬂuorescent probe JC-1 (2 μM; Biotium Inc.,
Hayward, CA), then centrifuged at 13,000 ×g for 5 min and re-sus-
pended in 0.5 mL PBS. The ﬂuorescence of each sample was read using
a Synergy HT Multi-Mode Microplate Reader (Bio-Tek Instruments): the
red ﬂuorescence, index of polarized mitochondria, was detected at
λ= 550 nm (excitation) and λ= 600 nm (emission); the green ﬂuor-
escence, index of depolarized and damaged mitochondria, was detected
at λ= 485 nm (excitation) and λ= 535 nm (emission). The ﬂuores-
cence units were used to calculate the percentage of green-ﬂuorescent
mitochondria versus red-ﬂuorescent mitochondria.
2.21. Caspase activity
Cells were lysed in 0.5 mL of caspase lysis buﬀer (20 mM HEPES/
KOH, 10 mM KCl, 1.5 mM MgCl2, 1 mM EGTA, 1 mM EDTA, 1 mM DTT,
1 mM PMSF, 10 μg/mL leupeptin, pH 7.5). 20 μg cell lysates were in-
cubated for 1 h at 37 °C with 20 μM of the ﬂuorogenic substrate of cas-
pase-9 Ac-Leu-Glu-His-Asp-7-amino-4-methylcoumarin (LEHD-AMC) or
of caspase-3 Ac-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin (DEVD-
AMC), in 0.25 mL caspase assay buﬀer (25 mM HEPES, 0.1% w/v 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 10%
w/v sucrose, 10 mM DTT, 0.01% w/v egg albumin, pH 7.5). The reaction
was stopped by adding 0.75 mL ice-cold 0.1% w/v trichloroacetic acid
and the ﬂuorescence of AMC fragment released by active caspases was
read using a LS-5 spectroﬂuorimeter (PerkinElmer). Excitation and
emission wavelengths were 380 nm and 460 nm, respectively.
Fluorescence was converted in pmoles/μg cell proteins, using a calibra-
tion curve prepared previously with standard solutions of AMC.
2.22. In vitro metabolic stability of nitrooxy-doxorubicin in rat and human
liver microsomes
ND, dissolved in water, was incubated at 10 μM concentration in
100 mM PBS with either 0.48 mg/mL RLM or human HLM proteins, as
previously reported [26]. The enzymatic reactions were initiated by
addition of a NADPH-regenerating system (NADPH-GS) consisting of
2 mM β-NADPH, 10 mM glucose-6-phosphate (G6P), 0.4 U/mL glucose-
6-phosphate dehydrogenase. Reactions were terminated at regular time
intervals (overall range 0–60 min) by adding a double volume of
acetonitrile. HPLC analysis was performed on Agilent 1100 Series liquid
chromatography system (Agilent Technologies, Palo Alto, CA, USA)
equipped with a LiChroCART® 250–4,6 (Merck Millipore, Vimodrone,
Italy) and coupled with UV-VIS detector, set at λ= 234 nm. Analysis
was carried out using gradient elution of a binary solution: eluent A was
acetonitrile, eluent B consisted of an aqueous solution of formic acid
(0.1%). The analysis started at 0% A for 3 min, then rapidly increased
up to 98% in 12 min and ﬁnally remaining at 98% A until 18 min. The
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analysis was performed at ﬂow rate of 0.8 mL/min and injection vo-
lume was 20 μL. The intrinsic clearance (Clint) was calculated by the
equation:
= ×
−Cl k(min ) [V]/[P]int 1
where k is the rate constant for the depletion of substrate, V is the
volume of incubation in μL and P is the amount of microsomal proteins
[27].
2.23. Inhibition of CYP-activity
RLM were incubated with the pentoxyresoruﬁn (PTR; substrate of
CYP2B), ethoxyresoruﬁn (ETR; substrate of CYP1A), benzyloxyresoruﬁn
(BZR, substrate of CYP1A, 2B, 2C and 3A), p-nitrophenol (PNF, substrate
of CYP2E1) and [3-[(3,4-diﬂuorobenzyl)oxy]-5,5-dimethyl-4-[4-(me-
thylsulfonyl)phenyl]furan-2(5H)-one] (DFB, substrate of CYP3A4) in
presence of 10 μmol/L ND, as previously reported [26]. Reactions were
started by adding NADPH-GS. To study the type of ND-induced inhibi-
tion, RLM were pre-incubated with 10 μM ND for 15 min, in presence or
absence of NADPH, and after 15 min, substrates were added to assay
mixture. The eﬀect of ND on phase II metabolism (glucuronyl and sul-
phate- transferase) was studied by using rat liver “precision cut” slices
and 7-ethoxycumarine as substrate, as previously reported [28]: liver
slices were incubated in 750 μL RPMI medium containing 10 μM ND and
50 μM ethoxycumarine. After 4 h incubation the formation of 7-OH-cu-
marine, 7-O-glucuronyl– and 7-O-sulphate cumarine were measured
ﬂuorimetrically at λ excitation = 370 nm, λ emission = 455 nm.
2.24. Metabolism modelling
The MetaSite computational procedure (version 5.1.1, https://
www.moldiscovery.com/software/metasite; Molecular Discovery Ltd.,
Hertfordshire, UK) was used to perform an in silico analysis aimed at
identifying possible metabolites and CYP isoforms involved in ND me-
tabolism [29].
2.25. In vivo tumor growth
1 × 105 TUBO cell suspension, mixed with 100 μL Matrigel, were
injected subcutaneously in 6 weeks-old female BALB/c mice, housed (5
per cages) under 12 h light/dark cycle, with food and drinking provided
ad libitum. The tumor growth was measured daily by caliper and was
calculated according to the equation (L ×W2) / 2, where L = tumor
length; W= tumor width. In a ﬁrst experimental setting, when the
tumor reached the volume of 100 mm3 (day 21), mice were randomly
divided in the following groups (8 mice/group) and treated on days 3, 9,
15 after randomization as it follows: 1) ctrl group, treated with 0.1 mL
saline solution intravenously (i.v.); 2) Dox group, treated with 5 mg/kg
doxorubicin i.v.; 3) Caelyx® group, treated with 5 mg/kg Caelyx® i.v.; 4)
ND group, treated with 5 mg/kg of the compound i.v.; 5) liposome ND,
treated with 5 mg/kg of the compound i.v.; 6) folate-targeted liposomal
ND group, treated with 5 mg/kg of the compound i.v. Tumor volumes
were monitored daily by caliper and animals were euthanized by in-
jecting i.m. zolazepam (0.2 mL/kg) and xylazine (16 mg/kg) at day 21
after randomization. Tumors were excised and photographed. In a
second experimental setting, mice were inoculated with 100 mm3-TUBO
cells, randomly divided 3 days after inoculation and treated as reported
above on day 3, 9 and 15 after tumor inoculation. Tumor growth was
monitored until day 54, then animals were sacriﬁced. In a third experi-
mental setting, mice bearing a 100 mm3-tumor were randomly divided
and treated on days 3, 9, 15 after randomization with 0.1 mL saline so-
lution i.v. or with 5 mg/kg of LNDF i.v. (“Drug ON” period). Animals
were left untreated for 2 weeks (“Drug OFF period”), subjected to the
same treatment (i.e. 5 mg/kg LNDF i.v., once a week for 3 weeks on days
30, 36, 42 after randomization; “Drug ON” period), left untreated for
2 weeks (“Drug OFF period”) and sacriﬁced on day 54. Tumors were
excised, digested by mechanical dissociation followed by 1 h incubation
in complete culture medium containing 1 mg/mL collagenase and
0.2 mg/mL hyaluronidase, for 1 h at 37 °C, then centrifuged at 12,000 x g
for 5 min, plated in fresh medium and used and used until passage 10–12
after plating. From mice of each experimental setting, tumors, heart,
liver, kidneys and lungs were collected, ﬁxed in 0.4% v/v paraf-
ormaldehyde for 18 h, washed with PBS and cut into 1 mm3-pieces.
Tissues were re-suspended into 1 mL ethanol/HCl 0.3 N, then homo-
genized for 30 s at 15 Hz, using a TissueLyser II device (Qiagen, Hilden,
Germany). An aliquot of the homogenates was used to measure the tissue
proteins; the remaining part was used to measure the content of doxor-
ubicins by ﬂuorimetric assays, as described above. The ﬂuorescence of
the corresponding tumors and organs of untreated animals (“ctrl”
groups), considered as intrinsic auto-ﬂuorescence, was subtracted from
the ﬂuorescence of each corresponding tumor/organs sample of treated
mice. Animal care and experimental procedures were approved by the
Bio-Ethical Committee of the Italian Ministry of Health (#122/2015-PR).
2.26. Hematochemical parameters
The hematochemical parameters LDH, aspartate aminotransferase
(AST), alanine aminotransferase (ALT), alkaline phosphatase (AP),
creatinine, CPK-MB were measured on the same blood samples col-
lected immediately after mice sacriﬁce, using commercially available
kits from Beckman Coulter Inc. (Miami, FL). c-Tnt was measured with
the Elecsys STAT immunoassay (Roche Diagnostics, Indianapolis, IN).
2.27. Immunoistochemistry analysis
Tumors and hearts were ﬁxed in 4% v/v paraformaldehyde. The
paraﬃn sections were stained with hematoxylin/eosin. Tumor sections
were immunostained for Ki67 (Millipore, Billerica, CA), an index of cell
proliferation, followed by a peroxidase-conjugated secondary antibody
(1:100, Dako, Glostrup, Denmark), or stained with the In Situ Cell Death
Detection Kit (Sigma Chemicals Co.), based on dUTP Nick End Labeling
(TUNEL) staining as an index of intratumor apoptosis. Heart sections
were stained with picrosirius red solution to detect ﬁbrosis [30], with
wheat germ agglutinin-Alexa Fluor™ 488 conjugate (Molecular Probes,
Eugene, OR) as index of cell dimension. To detect inﬂammatory cells,
permeabilized heart sections were treated with 0.3% H2O2 for 10min to
block endogenous peroxidases and with citric buﬀer for 10 min to un-
mask the antigen. After saturation, sections were immunostained with
an anti-CD18 antibody (BMA Biomedicals, Augst, Switzerland), fol-
lowed by a biotinylated anti-rat secondary antibody. Sections were ﬁ-
nally incubated with 3,3′-diaminobenzideine (DAB) solution for 5 min
and counterstained with hematoxylin, and examined with a Leica
DC100 microscope and/or Leica Olympus provis AX70 (Leica Micro-
systems GmbH, Wetzlar, Germany; 10 × ocular lens,
20–40–60–100 × objective, depending on the assay). At least 5 mi-
croscope ﬁelds were analyzed for each condition.
2.28. Statistical analysis
All data in the text and ﬁgures are provided as means ± SD. The
results were analyzed by a one-way analysis of variance (ANOVA) and
Tukey's test, using Statistical Package for Social Science (SPSS) software
(IBM SPSS Statistics v.19). p < 0.05 was considered signiﬁcant.
3. Results
3.1. Preparation and characterization of folate-targeted liposomal nitrooxy-
doxorubicin
To prepare folate-decorated liposomal nitrooxy-doxorubicin (LNDF)
two diﬀerent approaches were used and compared with respect to their
technological features and in vitro eﬀects. FA-PEG-DSPE conjugate was
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associated to liposomes either by addition during the preparation of the
lipid ﬁlm (LNDFm, resulting in the random orientation of folate on the
external surface and into the aqueous core of liposomes) or by post
insertion method by which the conjugate is micellized and incubated
with pre-formed liposomes (LNDFpi, all targeting ligands are on the
external leaﬂet of the liposomes).
The physicochemical characteristics of the diﬀerent formulations
are summarized in Table 1.
Liposomes displayed a dimensional range from about 180 nm to
205 nm and the particle size tended to increase in the folate-decorated
formulations. All formulations showed a low polydispersity index,
below 0.15, indicating a narrow and homogenous size distribution.
Liposomes showed a negative zeta potential value that was lower for
decorated liposomes compared to plain ones, due to the presence of
folate negatively charged carboxylic group. In particular, the negative
charge slightly decreased in the formulations prepared by post insertion
method suggesting a higher amount of folate on liposomes surface. On
the other hand, a strong decrease in the amount of ND encapsulated was
observed in LNDFpi, indicating a release of ND from liposomes during
the post insertion process. The amount of folate on the liposome surface
was determined spectrophotometrically; as shown in Table 2 the
amount of ligand was higher on liposomes prepared by post insertion
method as already observed for other formulations [31].
After 4 weeks of storage in HEPES buﬀer at 4 °C no appreciable li-
posomes size and/or zeta potential changes were detected for all for-
mulations and no liposomes aggregation or precipitation was observed.
After dilution with HEPES buﬀer or FCS, liposomes did not show
aggregation, even after 48 h at 37 °C and only in FCS an increase of the
mean diameter was observed (up to about 400 nm).
ND leakage from liposomes was evaluated in FCS and HEPES buﬀer
at 37 °C: the release proﬁle of ND from folate-targeted liposomes was
quite similar to that observed for previously tested untargeted ones [13]
(50% of the compound was released after 24 h in buﬀer and after 16 h
in serum).
3.2. Folate-targeted liposomal nitrooxy-doxorubicin is highly retained and
cytotoxic in Dox-resistant breast cancer cells
After a preliminary screening of the expression of folate receptor,
Pgp and MRP1 in not-transformed epithelial breast MCF10A cells and in
a panel of human and murine breast cancer cell lines (Supplementary
Fig. 1A), we selected human MCF7 cells, which had undetectable Pgp
and MRP1 and very low expression of FAR on cell surface [32], human
triple-negative MDA-MB-231 and murine TUBO cells, which had both
high expression of Pgp and MRP1 (Supplementary Fig. 1A) and surface
FAR (Supplementary Fig. 1B).
In time-course experiments, all the liposomal formulations
containing ND were signiﬁcantly more retained than free Dox and ND
in Pgp-/FAR-negative MCF7 cells, without - as expected because of the
absence of FAR - signiﬁcant diﬀerences between formulations with or
without FA (Fig. 1A). By contrast, in both MDA-MB-231 and TUBO
cells, the rank of intracellular doxorubicins retention followed this
order: LNDF > LND > ND > Dox (Fig. 1A). LNDFpi were slightly
more accumulated than LNFDm (Fig. 1A), likely as a consequence of the
higher amount of FA present on liposome surface. LNDFm and LNDFpi
were less slightly accumulated at 1–3 h in TUBO cells compared to
MDA-MB-231 cells, but no signiﬁcant diﬀerences were detected at later
time points (Fig. 1A). For both formulation types, the liposome uptake
was FAR-speciﬁc, as suggested by competition assays (Supplementary
Fig. 2). In all cell lines the amount of Dox and ND gradually decreased
at 48 or 72 h compared to 24 h. By contrast, the amount of Dox in cells
treated with LND or LNDF, was stable at 48 and 72 h, either in Pgp-
negative MCF7 cells or in Pgp-positive MDA-MB-231 and TUBO cells
(Fig. 1A).
In MCF7 cells, but not in MDA-MB-231 and TUBO cells, Dox in-
creased nitrite release (Fig. 1B). In all cell lines, free ND or LND in-
creased nitrite levels more than Dox. In the FAR-positive MDA-MB-231
and TUBO cells, LNDF produced the highest release of nitrite (Fig. 1B),
in line with the higher compound uptake in these cells.
Higher are the intracellular retention of doxorubicines and the in-
crease of NO, higher is the cytotoxicity [8,11,13]. Consistently, the
acute cytotoxicity, measured by the extracellular release of LDH
(Fig. 1C) and the reduction on cell survival, measured by the neutral red
staining (Fig. 1D), followed the trend of compound accumulation and
nitrite levels.
LNDF formulations were not more accumulated than free Dox, ND
or LND in FAR-negative/Pgp-negative not-transformed breast epithelial
MCF10A cells (Supplementary Fig. 3A), they did not increase the re-
lease of LDH (Supplementary Fig. 3B) nor reduced cell viability more
than Dox (Supplementary Fig. 3C). Overall, LNDF induced less cyto-
toxicity in MCF10A cells than in MCF7 breast cancer cells (Fig. 1).
The anti-tumor observed eﬀects were not tumor-type speciﬁc: in-
deed, in human osteosarcoma U-2OS cells, which had high expression
of FAR (Supplementary Fig. 4A), LNDF was accumulated
(Supplementary Fig. 4BeC), increased nitrite (Supplementary Fig. 4D)
and LDH release (Supplementary Fig. 4E), decreased cell viability
(Supplementary Fig. 4F) more than Dox, ND or LND. Starting from
these data, we are currently expanding the investigation on the eﬃcacy
of LNDF on diﬀerent Pgp-/FAR-positive tumors.
3.3. Folate-targeted liposomal nitrooxy-doxorubicin induces cell death with
mitochondria- and nuclei- dependent mechanisms
As previously observed, Dox has a typical nuclear localization,
Table 1
Characteristics of liposomes containing nitrooxy-doxorubicin (means, n= 3).
Formulation Mean particle size (nm ± SD) Polydispersity index Zeta potential (mV ± SD) Entrapment eﬃciency (%)a
LND 182 ± 5.1 0.119 −7.53 ± 0.6 90.6 ± 4.1
LNDFm 194 ± 4.0 0.148 −10.9 ± 0.5 95.2 ± 2.9
LNDFpi 205 ± 2.2 0.121 −13.6 ± 0.9 66.1 ± 3.2
a Ratio between drug/lipid molar ratio after puriﬁcation and drug/lipid molar ratio after extrusion.
Table 2
Characteristics of folate-liposomes (means, n= 3).
Formulation Folate content (μM ± SD) FA/La (%) Folate insertion eﬃciencyb (%) Average number of folate molecules inserted per liposome
LNDFm 18.1 ± 5.1 1.11 ± 0.21 30.7 ± 5.7 2820
LNDFpi 38.3 ± 5.4 2.43 ± 0.30 67.0 ± 7.7 5570
a Ratio between moles of folate on liposome surface and moles of lipids in the ﬁnal liposomal suspension.
b Ratio between moles of folate on liposome surface and moles of lipids in the ﬁnal liposomal suspension and the theoretical value.
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whereas ND – either as free drug or liposomal formulation – had a
peculiar mitochondrial accumulation [13]. Dox had low intranuclear
(Fig. 2A, B) and intramitochondrial (Fig. 2C, D) in MDA-MB-231 cells,
in consequence of its poor intracellular accumulation (Fig. 1A). ND and
LND LNDF displayed low intranuclear localization (Fig. 2A, B) and
relevant intramitochondrial localization (Fig. 2C, D). Curiously, LNDF
delivered drug to both nuclei and mitochondria (Fig. 2A-D). The
ﬂuorescence and confocal microscope ﬁndings were conﬁrmed by the
HPLC quantiﬁcation of compounds in nuclear and mitochondria ex-
tracts (Supplementary Fig. 5).
Dox elicits antitumor eﬀects by inhibiting topoisomerase II activity,
inducing cell cycle arrest and DNA damage, and by several other me-
chanisms, including the impairment of mitochondrial energy metabo-
lism and the generation of ROS via the mitochondrial electron transport
chain [33]. We thus investigated the mechanisms at the basis of higher
cytotoxic eﬃcacy of LNDF, hypothesizing that both nucleus- and mi-
tochondria-dependent mechanisms can be involved.
Dox did not induce cell cycle arrest in drug resistant MDA-MB-231
cells (Fig. 3A) or genotoxic eﬀects, evaluated by COMET assay (Fig. 3B;
Supplementary Fig. 6). Also ND and LND did not alter the cell cycle
Fig. 1. Doxorubicins uptake in breast cancer cells.
A. Pgp-/FAR-negative MCF7 cells, Pgp-/FAR-positive MDA-MB-231 and TUBO cells were incubated for 0, 1, 3, 6, 24, 48 and 72 h with 5 μM Dox (D), nitrooxy-doxorubicin (ND),
liposomal nitrooxy-doxorubicin (LND), liposomal nitrooxy-doxorubicin decorated with folate added in the phospholipids mixture (LNDFm) or by post insertion (LNDFpi) technique. The
intracellular amount of Dox was measured ﬂuorimetrically in duplicate. Data are presented as means ± SD (n= 4). LNDFm/LNDFpi vs D: *p < 0.001; LNDFm/LNDFpi vs ND:
°p < 0.01; LNDFm/LNDFpi vs LND: #p < 0.001. B. Cells were grown as reported in A for 24 h. Nitrite levels in the cell supernatant, an index of NO amount, were measured
spectrophotometrically in duplicate in the cell culture supernatant. Data are presented as means ± SD (n = 4). Vs untreated (−) cells: *p < 0.001; ND/LND/LNDFm/LNDFpi vs D:
°p < 0.01; LNDFm/LNDFpi vs ND: #p < 0.001; LNDFm/LNDFpi vs LND: §p < 0.001. C. Cells were grown as reported in A for 24 h. The release of LDH in the cell culture supernatant,
was measured spectrophotometrically in duplicate. Data are presented as means ± SD (n = 4). Vs untreated (−) cells: *p < 0.001; ND/LND/LNDFm/LNDFpi vs D: °p < 0.05; LNDFm/
LNDFpi vs ND: #p < 0.002; LNDFm/LNDFpi vs LND: §p < 0.005. D. Cells were grown as reported in A for 72 h. Cell viability was measured in quadruplicate by neutral red staining
method. Data are presented as percentage of viable cells towards untreated cells (n = 4). Vs untreated (−) cells: *p < 0.001; ND/LND/LNDFm/LNDFpi vs D: °p < 0.002; LNDFm/
LNDFpi vs ND: #p < 0.05; LNDFm/LNDFpi vs LND: §p < 0.01.
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distribution, except for an increase of sub-Go cells, suggestive of
apoptotic cells (Fig. 3A) and did not produce signiﬁcant DNA damages
(Fig. 3B; Supplementary Fig. 6). Although both ND and LND were cy-
totoxic also in drug resistant cells (Fig. 1C–D), their prevalent mi-
tochondrial localization likely prevented the toxicity dependent on
nuclear mechanisms. By contrast, the higher nuclear delivery of LNDF
made the drug able to exert nuclear toxicity, as demonstrated by the
wide alteration of cell cycle distribution (i.e. the increased percentage
of sub-Go cells and of cells arrested in G2/M phase, Fig. 3A) and by the
signiﬁcant genotoxicity (Fig. 3B; Supplementary Fig. 6).
Dox did not exert any mitochondrial-dependent cytotoxicity in
resistant MDA-MB-231 cells; e.g. it did not increase intra-mitochondrial
reactive nitrogen species RNS (Fig. 3C) and ROS (Fig. 3D), it did not
impair tricarboxylic acid (TCA) cycle (Fig. 3E), electron transport
(Fig. 3F), ATP levels (Fig. 3G) and mitochondrial membrane potential
(Fig. 3H), and it did not activate caspase 9 (Fig. 3I) and caspase 3
(Fig. 3J). By contrast, ND - as free drug, LND or LNDF - increased intra-
mitochondrial RNS and ROS, decreased TCA cycle, electron ﬂux and
ATP amounts, induced mitochondrial depolarization and caspase 9/3
activation (Fig. 3C–J), likely in consequence of the high intra-mi-
tochondrial accumulation of ND achieved with all these formulations
(Fig. 2B and D).
Fig. 2. Intracellular distribution of folate-targeted liposomal nitrooxy-doxorubicin.
A. Pgp-/FAR-positive MDA-MB-231 cells were incubated 6 h with 5 μM Dox (D), nitrooxy-doxorubicin (ND), liposomal nitrooxy-doxorubicin (LND), liposomal nitrooxy-doxorubicin
decorated with folate added in the phospholipids mixture (LNDFm) or by post-insertion method (LNDFpi), ﬁxed and counterstained with DAPI, then analyzed for the intracellular
doxorubicins (Doxo) localization by ﬂuorescence microscopy. The micrographs are representative of three experiments with similar results. Bars: 20 μm. B. Nuclear ﬂuorescence
quantiﬁcation by ImageJ software. Fluorescence units in Dox-treated cells were considered as 1. Results were means ± SD of three independent experiments. ND/LND/LNDFm/LNDFpi
vs D: *p < 0.001; LNDFm/LNDFpi vs ND: °p < 0.001; LNDFm/LNDFpi vs LND: #p < 0.001. C. Cells were transfected with expression vectors encoding for the GFP-fused-leader
sequence of E1 α pyruvate dehydrogenase to label mitochondria (mito) for 18 h, then incubated as reported in A. The intracellular Doxo localization by confocal microscopy. The
micrographs are representative of three experiments with similar results. Bars: 10 μm. D. Mitochondrial ﬂuorescence quantiﬁcation by ImageJ software. Fluorescence units in Dox-treated
cells were considered as 1. Results were means ± SD of three independent experiments. ND/LND/LNDFm/LNDFpi vs D: *p < 0.001. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
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3.4. Nitrooxy-doxorubicin is metabolically stable
The metabolic stability of ND was assessed in rat liver microsomes
(RLM) and human liver microsomes (HLM). The cytochrome P450
(CYP)-dependent metabolism of ND followed a classic ﬁrst order decay
kinetic. The calculated intrinsic clearance (Clint) values were similar in
both preparations (Supplementary Table 1) and suggested a high me-
tabolic stability [27]. ND did not change the depletion rate of substrates
(caption on next page)
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of most rat CYP isoforms (data not shown), with the exception of 3-
[(3,4-diﬂuorobenzyl)oxy]-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]
furan-2(5H)-one (DFB), a substrate of CYP3A4. In this case, the for-
mation rate of the product (3-hydroxy-5,5-dimethyl-4-[4-(methylsul-
fonyl)phenyl]furan-2(5H)-one, DFH) was inhibited in a competitive
manner by 15% and 20% after 15 and 30 min incubation time, re-
spectively (Supplementary Fig. 7A). Since DFB is O-dealkylated to DFH
to a similar extent by rat CYP3A2 and human CYP3A4 isoforms [34],
this result suggests that CYP3A isoform is the main isoenzyme involved
in ND metabolism in both mammalian species. These data were sup-
ported by the in silico prediction of ND metabolites (Metasite software),
that conﬁrmed that CYP3A is the main isoform involved in the human
metabolism of ND (with a minor contribution of CYP2D6 and CYP2C19)
and indicated that the O-demethylate derivative is the most probable
metabolite.
Phase II metabolism was minimally aﬀected by ND: although ND
reduced the formation of phase I metabolite 7-OH cumarine (-15%) and
of phase II sulphate metabolite (-25%), such decrease was not statisti-
cally signiﬁcant. Also the amount of glucuronide products did not diﬀer
in the absence or in the presence of ND (Supplementary Fig. 7B). The
latter results, obtained in “precision-cut” rat liver slices, an in vitro
model closely resembling the in vivo conditions, allow us to hypothesize
that ND can aﬀect the in vivo CYP activities at lower extent than the
parent compound Dox [35].
3.5. Folate-targeted liposomal nitrooxy-doxorubicin is eﬀective against Pgp-
positive tumors in vivo
On the basis of the promising results obtained by LNDF in vitro and
the good metabolic proﬁle of ND, we next validated the eﬃcacy of
LNDF in the pre-clinical model of Pgp-/FAR-positive cells, implanting a
lethal amount of TUBO cells in syngeneic female BALB/c mice [36]
(Fig. 4A). Since the liposomes prepared by adding folate in the phos-
pholipids mixture (LNDFm) or by post insertion (LNDFpi) technique
gave superimposable results in all the assays in vitro, we only used the
former formulation - that was characterized by higher amount of en-
capsulated ND - for the in vivo experiments (named as LNDF). Dox - as
well as Caelyx® - did not reduced tumor growth (Fig. 4B–C), whereas
the ND formulations were progressively more eﬀective, following this
rank order: ND < LND < LNDF (Fig. 4B–C). The reduced tumor
growth was paralleled by a progressive decrease of tumor cell pro-
liferation, as revealed by Ki67 staining, and by a progressive increase of
intratumor apoptotic areas, as revealed by TUNEL staining (Fig. 4D).
This pattern replicates in vivo the main anti-proliferative mechanisms
exerted by LNDF in vitro. The growth of TUBO tumors is signiﬁcantly
reduced by 15 mg/Kg Dox or Caelyx® [37]. We achieved a signiﬁcant
reduction of tumor growth with a three-fold lower dose of LNDF.
In addition, when administered for 3 weeks starting at early stages
of tumor development, i.e. 3 days after tumor implants (Fig. 5A), LNDF
and – at lesser extent – ND and LND eﬀectively retarded tumor growth,
diﬀerently from free Dox or Caelyx® (Fig. 5B–C).
In our experimental conditions, Dox did not alter cardiac tissue
morphology, did not induce ﬁbrosis, did not increase intracardiac in-
ﬁltration of inﬂammatory cells and did not induce signiﬁcant changes
in cardiomyocyte cross sectional area (Supplementary Fig. 8). LNDF did
not alter these parameters as well (Supplementary Fig. 8). The only
signs of cardiac toxicity induced by Dox – in both experimental setting
of Figs. 4 and 5 – was the increase in cardiac troponin (c-Tnt; Supple-
mentary Tables 2–3), as it usually occurs for a cumulative dose of
Dox > 12 mg/kg [38]. As expected, Caelyx® prevented c-Tnt increase.
Of note, LND and LNDF were similar to Caelyx®. Also, they did not
induce liver or kidney toxicity, according to the hematochemical
parameters (Supplementary Tables 2–3).
In line with the diﬀerent reduction of tumor growth and the he-
matochemical parameters, in both experimental settings described
above (Fig. 4–5), ND, LND and LNDF were more retained than Dox and
Caelyx® within the tumors, following this order: LNDF > LND > ND
(Supplementary Fig. 9A–B). Dox was the drug mostly accumulated
within heart, followed by ND. The intracardiac accumulation of LND
and LNDF was similar to Caelyx® (Supplementary Fig. 9A–B). All lipo-
somal formulations (Caelyx®, LND and LNDF) were more accumulated
than free drugs (Dox and ND) in liver (Supplementary Fig. 9A–B), al-
though such accumulation was apparently not associated to liver da-
mage, as suggested by the lack in increase of transaminase, alkaline
phosphatase and LDH (Supplementary Tables 2–3). No signiﬁcant dif-
ferences were detected in the levels of free drugs and liposomal for-
mulation in kidneys. Interestingly, Caelyx®, LND and LNDF resulted less
accumulated than Dox or ND in lungs (Supplementary Fig. 9A–B).
Dox dose-dependently increased the acute cardiotoxicity, inducing
signiﬁcant increase of creatine-phosphate kinase (CPK-MB) and c-Tnt at
12.5 mg/kg and 25 mg/kg dosages (Supplementary Table 4). Caelyx®
and the liposomal formulations of ND did not elicit any acute increase
of these parameters at each dosage tested (Supplementary Table 4),
suggesting that liposomal formulations of ND had a cardiovascular
safety proﬁle superior to Dox and comparable to Caelyx®.
3.6. Cells treated with folate-targeted liposomal nitrooxy-doxorubicin retain
the same sensitivity of chemonaïve cells to the drug
To evaluate whether the response of tumors to LNDF was progres-
sively reduced over the time, animals bearing a 100 mm3-tumor were
subjected to 2 cycles of treatment with LNDF (one LNDF administra-
tion/week for 3 consecutive weeks) followed by a 2-week drug-holiday
period (Fig. 6A). The rate of tumor growth remained low either after
the ﬁrst or the second cycle of treatment (Fig. 6B), and the ﬁnal tumor
volume was signiﬁcantly lower than the volume of animals receiving
vehicle (Fig. 6C). Also in this experimental setting, animals treated with
repeated cycles of LNDF did not had signs of liver, kidney or heart
toxicity (Supplementary Table 5). The amount of Dox in tumors and
organs in animals treated with LNDF was lower in this experimental
setting (Supplementary Fig. 9C), where the animal sacriﬁce occurred
2 weeks after the last treatment than in the previous experimental
settings, where the mice sacriﬁce occurred 1 week after the last LNDF
administration (Supplementary Fig. 9A–B).
Fig. 3. Nucleus- and mitochondria-dependent cytotoxic eﬀects folate-targeted liposomal nitrooxy-doxorubicin in resistant cells.
Pgp-/FAR-positive MDA-MB-231 cells were incubated 24 h in fresh medium (−) or in medium containing 5 μM Dox (D), nitrooxy-doxorubicin (ND), liposomal nitrooxy-doxorubicin
(LND), liposomal nitrooxy-doxorubicin decorated with folate added in the phospholipids mixture (LNDFm) or by post-insertion method (LNDFpi). In panel A–B gemcitabine (50 μM for
24 h, GEM) was used as control of DNA damaging agent. A. The cell cycle distribution was measured by ﬂow cytometry. Data are presented as means ± SD (n= 3). Vs untreated (−)
cells: *p < 0.05. B. DNA damage was assessed by Comet assay. The microphotographs are representative of DNA comets obtained in 3 experiments with similar results. Bars = 10 μm.
C–D. Intramitochondrial RNS (panel C) were measured in duplicate by a speciﬁc ELISA, intramitochondrial ROS (panel D) were measured in duplicate ﬂuorimetrically. Data are presented
as means ± SD (n = 4). For both panels, vs untreated (−) cells: *p < 0.01; ND/LND/LNDFm/LNDFpi vs D: °p < 0.01. E. The glucose ﬂux through TCA cycle was measured in cells
radiolabeled with [6-14C]-glucose. Data are presented as means ± SD (n = 3). Vs untreated (−) cells: *p < 0.01; ND/LND/LNDFm/LNDFpi vs D: °p < 0.01. F–G. The electron ﬂux
between Complex I and III (panel F) was measured spectrophotometrically in duplicate, the ATP amount (panel G) was measured by a chemiluminescence-based assay in duplicate in
isolated mitochondria. Data are presented as means ± SD (n = 3). For both panels, vs untreated (−) cells: *p < 0.005; ND/LND/LNDFm/LNDFpi vs D: °p < 0.05. H. The mi-
tochondrial membrane potential was assessed by the JC-1 staining method in duplicate. The percentage of green versus red mitochondria was considered an index of mitochondrial
depolarization and permeability transition. Data are presented as means ± SD (n = 3). Vs untreated (−) cells: *p < 0.001; ND/LND/LNDFm/LNDFpi vs D: °p < 0.001. I–J. The
activity of caspase 9 (panel I) and 3 (panel J) was measured ﬂuorimetrically in the cytosolic extracts. Data are presented as means ± SD (n= 3). For both panels, vs untreated (−) cells:
*p < 0.001; ND/LND/LNDFm/LNDFpi vs D: °p < 0.001. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Cells derived from treated tumors – re-plated and tested at passage
1, 5 (not shown) and 10–12 (Fig. 6D–F) - were still resistant to Dox in
terms of low drug accumulation (Fig. 6D), low cytotoxicity (Fig. 6E)
and high cell viability (Fig. 6F), but they retained the same sensitivity of
chemonaïve cells (Fig. 1A, C–D) to LNDF (Fig. 6D–F).
4. Discussion
In this work we validated the eﬃcacy of LNDF, a new FA-targeted
liposomal formulation carrying a Dox-derivative designed to bypass the
eﬄux mediated by Pgp, against breast cancer cells, where either free
Dox or Caelyx® were ineﬀective. The high expression of FAR is
commonly observed in Dox-resistant cells of diﬀerent histological origin
[39]. Of note, comparing Dox-sensitive and Dox-resistant 4T1 breast
cancer cells, FAR was signiﬁcantly up-regulated in the latter [40],
making FA-conjugated nanocarriers promising tools in increasing the
drug delivery within resistant cells. By exploiting this feature, we va-
lidated the anticancer eﬃcacy of LNDF in Pgp-highly expressing breast
cancer cell lines (i.e. MDA-MB-231 and TUBO cells) that showed a
lower response to doxorubicin – in terms of drug-induced cytotoxicity in
vitro – compared to Pgp-negative breast cancer MCF7 cells, and may be
considered a good model of tumors constitutively resistant to Dox.
LNDF uptake was lower in TUBO cells at 1–3 h, but it did not sig-
niﬁcantly diﬀer between TUBO and MDA-MB-231 cells over the period
Fig. 4. Anti-tumor eﬀects against of folate-targeted liposomal nitrooxy-doxorubicin against resistant tumors.
Six weeks-old female BALB/c mice bearing a 100 mm3-TUBO (i.e. Pgp-/FAR-positive) tumor were randomly divided in the following groups (8 mice/group) and treated on days 3, 9, 15
after randomization as it follows: 1) ctrl group, treated with 0.1 mL saline solution i.v.; 2) Dox (D) group, treated with 5 mg/kg doxorubicin i.v.; 3) Caelyx® group, treated with 5 mg/kg
Caelyx® i.v.; 4) nitrooxy-doxorubicin (ND) group, treated with 5 mg/kg of the compound i.v.; 5) liposomal nitrooxy-doxorubicin group (LND), treated with 5 mg/kg of the compound i.v.;
6) folate-targeted liposomal nitrooxy-doxorubicin (LNDF) group, treated with 5 mg/kg of the compound i.v. Animals were sacriﬁced at day 21 after randomization. A. Representative
scheme of the treatment protocol. B. Tumor growth monitored by caliper measurement. Data are presented as means ± SD. ND/LND/LNDF vs ctrl group: *p < 0.01; ND/LND/LNDF vs
D: °p < 0.01; LNDF vs ND: #p < 0.001; LNDF vs LND: §p < 0.05. C. Photographs of representative tumors from each treatment group after mice sacriﬁce. D. Sections of tumors from
each group of mice were stained with hematoxylin and eosin (HE), immunostained with antibodies for Ki67 as an index of proliferation, or subjected to TUNEL staining as an index of
apoptosis. Bar = 10 μm. The photograph is a representative of sections from ﬁve tumors. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the
web version of this article.)
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24–72 h, suggesting that our the delivery of doxorubicins induced by
LNDF formulations granted a stable and durable drug delivery. This
trend may be due to a lower endocytic rate of FAR in TUBO cells at
short term, that may be compensated by an eﬃcient FAR re-synthesis at
long term that makes the expression of surface FAR equal in both the
cell lines used.
Of note, in not-transformed breast epithelial MCF10A cells LNDF
did not exert a cytotoxicity superior to Dox and was less toxic than in
breast cancer cells with comparable undetectable levels of FAR and Pgp
(such as MCF7 cells). This can be due to the low intracellular accu-
mulation of LNDF and/or to the slow proliferation of MCF10A cells, a
well-known feature that makes not-transformed cells more susceptible
to DNA damaging agents like Dox than cancer cells. Since LNDF exerts
its antitumor eﬀects at signiﬁcantly lower concentrations than Dox, we
may reasonably suppose that it can be eﬀective against Pgp-positive
cancer cells at lower dosages than Dox, resulting less toxic than the
latter on not-transformed breast epithelia.
Two types of FA-liposomes were prepared and compared. We ob-
served that in LNDFm, in which the FA-PEG-DSPE conjugate was in-
cluded in the lipid ﬁlm prior to liposome formation, the targeting ligand
amount on liposome surface was approximately the half of that of
LNDFpi, in which the conjugate was inserted by post insertion tech-
nique in preformed liposomes. However, LNDFpi showed a decrease in
ND encapsulation eﬃciency; this can be due to a partial release of the
compound from liposomes during the post insertion process that was
done at a temperature near to the phase transition temperature of the
lipid mixture, since ND is located in the hydrophobic region of the
membrane bilayer, as we previously demonstrated [13]. The important
reduction of drug content in liposomes was not observed in other works
when Caelyx®, in which Dox is encapsulated in the aqueous phase of
liposomes, was decorated with FA using the same procedure [41].
However, the reduced amount of ND did not compromise the anti-
tumor properties, since we did not detect any signiﬁcant diﬀerences in
the biological eﬀects exerted by LNDFm and LNDFpi against Pgp-/FAR-
positive cells. Thus, LNDFm was used for the further in vivo experi-
ments.
It has been recently demonstrated that FA-targeted liposomes oﬀer a
signiﬁcant advantage in the controlled delivery and intracellular acti-
vation of mitomycin-C prodrug in FAR-positive cells [42]. Similarly, the
FA-decorated derivative of Caelyx® was more eﬀective than Dox and
Caelyx® against head and neck cancers over-expressing FAR [41].
However, the eﬃcacy against Pgp-expressing cells was not tested. Our
in vitro screening revealed that LNDF was accumulated in a FAR-de-
pendent way, was more retained and more cytotoxic than free Dox or
untargeted LND in Pgp-positive cells. In line with our data, FA-targeted
pegylated liposomes loaded with paclitaxel exerted higher cytotoxicity
against MDA-MB-231 cells than free paclitaxel or paclitaxel carried by
untargeted liposomes [43]. Similarly, FA-targeted and pH-sensitive
nanogels delivered Dox with high eﬃcacy in Pgp-positive 4T1 breast
cancer cells: this system allowed a signiﬁcant reduction of Dox IC50 in
resistant cells, independently on the presence of Pgp [40].
Paclitaxel and Dox are both Pgp substrate [1]. Taken together, these
results suggest that the delivery through FA-targeted pegylated lipo-
somes is a promising approach to increase the eﬃcacy of chemother-
apeutic drugs against FAR-positive and Pgp-positive cells. Since an-
thracyclines and taxanes are ﬁrst-line treatments in triple negative
breast cancer [17], our work may provide the rationale for validating
the eﬃcacy of FA-targeted liposomal ND in this type of breast cancer.
Of note, the higher accumulation of LNDF was paralleled by the
higher release of NO. We previously demonstrated that the nitration
Fig. 5. Early administration of folate-targeted liposomal nitrooxy-doxorubicin retards the growth of Dox-resistant tumors.
Six weeks-old female BALB/c mice were injected subcutaneously with 1 × 105 Pgp-/FAR-positive-TUBO cells. At day 3 after injection, animals were randomly divided in the following
groups (8 mice/group) and treated on days 3, 9, 15 after tumor inoculation as it follows: 1) ctrl group, treated with 0.1 mL saline solution i.v.; 2) Dox (D) group, treated with 5 mg/kg Dox
i.v.; 3) Caelyx® group, treated with 5 mg/kg Caelyx® i.v.; 4) nitrooxy-doxorubicin (ND) group, treated with 5 mg/kg of the compound i.v.; 5) liposomal nitrooxy-doxorubicin group (LND),
treated with 5 mg/kg of the compound i.v.; 6) folate-targeted liposomal nitrooxy-doxorubicin (LNDF) group, treated with 5 mg/kg of the compound i.v. Tumor growth was monitored
until day 54, then animals were sacriﬁced. A. Representative scheme of the treatment protocol. B. Tumor growth was monitored by caliper measurement. Data are presented as
means ± SD. ND/LND/LNDF vs ctrl group (from day: *p < 0.01; ND/LND/LNDF vs D: °p < 0.01; LNDF vs ND: #p < 0.001; LNDF vs LND: §p < 0.05. C. Photographs of re-
presentative tumors from each treatment group after mice sacriﬁce. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
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and subsequent inhibition of drug eﬄux transporters [11,13] triggers a
“virtuous circle” that allows the increased retention of ND and toxicity.
Moreover, we also demonstrated that the encapsulation of Dox into
pegylated liposomes reduces Pgp activity: ﬁrst, the phospholipids of the
liposomal shell alter the plasma-membrane lipid environment where
Pgp works [44]; second, pegylated distearoyl-phosphatidylethanola-
mine, a component of liposomal formulations, acts as an allosteric in-
hibitor of Pgp [45]. These inhibitory eﬀects exerted by liposomal for-
mulation on Pgp expression and activity [44–47] provide an additional
beneﬁt of LND and LNDF over free Dox of ND at long term. Indeed,
while Dox and ND intracellular retention decreased 48 and 72 h after
the exposure to the drug, likely reﬂecting the ND metabolism into Dox
and further catabolites such as doxorubicinol [11] and/or the sub-
sequent eﬄux of free Dox by Pgp, the amount of LND and LNDF
remained stable. It is likely that FA-decoration, liposome encapsulation,
pegylated phospholipids all contribute to the increase drug delivery
and/or to the reduced eﬄux of ND form Pgp-/FAR-positive cells.
While Dox had a typical nuclear delivery and ND or LND had a
typical mitochondrial localization [11,13], a peculiarity of LNDF was
the delivery of its cargo to both nucleus and mitochondria. Mitochon-
drial delivery may be explained by the presence of ND, that has a strong
tropism for mitochondria [11]. On the other hand, FAR has been de-
tected in cytosol and nuclear compartments in ovary cancer biopsies
[48]. It has been proposed that FAR localized on plasma-membrane
follows an endosomal-lysosomal-mediated endocytic pathway, and that
it migrated into the nucleus after the release from lysosomes [49]. Al-
though we did not investigate the endocytic fate of FAR upon LNDF
binding, the presence of intranuclear Dox in LNDF-treated cells
Fig. 6. Doxorubicin-resistant tumors treated with folate-targeted liposomal nitrooxy-doxorubicin do not develop resistance after two cycles of treatment.
Six weeks-old female BALB/c mice bearing a 100 mm3-TUBO (i.e. Pgp-/FAR-positive) tumors were randomly divided in the following groups (10 mice/group) and treated on days 3, 9, 15
after randomization as it follows: 1) ctrl group, treated with 0.1 mL saline solution i.v.; 2) folate-targeted liposomal nitrooxy-doxorubicin (LNDF) group, treated with 5 mg/kg of the
compound i.v. (“Drug ON” period). Animals of ctrl group were sacriﬁced at day 24 after randomization for ethical reasons. Animals of LNDF group were left untreated for 2 weeks (“Drug
OFF” period), subjected to the same treatment described above (i.e. 5 mg/kg LNDF i.v., once a week for 3 weeks on days 30, 36, 42 after randomization; “Drug ON” period), then left
untreated for 2 weeks (“Drug OFF” period). Animals were sacriﬁced on day 54. Tumors from treated animals were excised, digested and re-plated for the ex vivo assays reported in panels
D–F. A. Representative scheme of the treatment protocol. B. Tumor growth was monitored by caliper measurement. Data are presented as means ± SD. For statistical analysis tumor
volume of LNDF group until day 24 was compared with the tumor volume of the corresponding day in the ctrl group; tumor volume of LNDF group from day 27 to day 54 was compared
with the tumor volume on day 24: *p < 0.001. C. Photographs of representative tumors from each treatment group after mice sacriﬁce. D. At passage 10–12 after re-plating, TUBO cells
obtained from digested tumors of LNDF-treated animals were incubated for 6 h with 5 μM Dox (D) or LNDF. The intracellular amount of compounds was measured ﬂuorimetrically in
duplicate. Data are presented as means ± SD (n= 3). LNDF vs D: *p < 0.001. E. Cells were grown for 24 h in fresh medium (−) or in medium containing 5 μM Dox or LNDF. The
release of LDH were measured spectrophotometrically in the cell culture supernatant in duplicate. Data are presented as means ± SD (n = 3). LNDF vs untreated (−) cells: *p < 0.001;
LNDF vs D: °p < 0.001. F. Cells were grown for 72 h as reported in E. Cell viability was measured in quadruplicate by neutral red staining method. Data are presented as percentage of
viable cells towards untreated cells (n = 3). LNDF vs untreated (−) cells: *p < 0.001; LNDF vs D: °p < 0.001. (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
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supports this model. Dual ligand-coupling strategies using liposomes
decorated with FA and dexamethasone [50] have been successfully
employed to increase the uptake of Dox and its nuclear delivery. Our
formulation of LNDF, coupling the FAR-mediated uptake with the mi-
tochondrial tropism of ND, oﬀers the advantage of the simultaneous
delivery of the chemotherapeutic drug to both nucleus and mitochon-
dria. LNDF exerted cytotoxicity by nuclear-dependent mechanism, i.e.
exerting classical pharmacodynamics eﬀects of Dox [33], and mi-
tochondrial-dependent mechanisms, i.e. reproducing the same eﬀects of
ND on mitochondria metabolism [11]. Triple negative breast cancers
usually have multiple mechanisms of drug resistance, including ABC
transporter overexpression, mutations in DNA repairing system en-
zymes, alterations in apoptosis [51]. Overcoming at the same time these
multiple mechanisms of resistance is a challenging task in triple nega-
tive breast cancer treatment. Our results suggest that LNDF may be an
eﬀective tool to achieve this goal, since it combines the beneﬁts derived
from the active targeting and the beneﬁts derived from the targeting of
multiple pathways triggering cell death.
According to the latest guidelines, anthracycline-based mono-
therapy is one of the recommended treatment in the advanced stages of
estrogen/progesterone receptor-negative breast tumors [52]. We then
validated the eﬃcacy of LNDF in preclinical models of estrogen/pro-
gesterone receptor-negative breast tumors, by inoculated a lethal
amount of Pgp−/FAR-positive TUBO cells in syngeneic Balb/C mice
[36]. This tumor model is characterized by fast grow, heavy inﬁltration
of circulating inﬂammatory cells, in particular of M1-polarized mac-
rophages that promote tumor growth and vascularization [53]. These
features, suggestive of disorganized and highly fenestrated intra-tumor
vasculature, favor the extravasation of liposomes as well. This hy-
pothesis was supported by the high intra-tumor Dox still found in tu-
mors 1 week after the last administration, that was 7.8-fold than free
Dox, 4.9-fold more than Caelyx®, 2-fold more than ND and 1.3-fold
more than LND. Since the one-pass circulation time of blood in mice is
around 15 s [54], that is much shorter than the release time of ND from
LNDF. Consistently, LNDF achieved greater therapeutic beneﬁts than
the currently used anthracycline-based regimens (i.e. Dox and Caelyx®)
on already formed tumors, suggesting that this liposomal formulation
eﬀectively delivered Dox within tumor core.
Interestingly, LNDF also delayed tumor growth when administered
during the early phases of tumor development. FA is avidly taken up by
rapidly dividing cells where it is used to support the synthesis of purines
and the reaction of thymidylate synthase. We hypothesize that this
biochemical need induces the high uptake of LNDF into rapidly growing
TUBO tumors, explaining its high eﬃcacy in preventing tumor growth.
At lesser extent, also LND and ND reduced the growth of already
formed tumors and delayed tumor formation: this property may be due
to the anti-cancer properties of NO [55], coupled with the concomitant
delivery of drug. In line with the higher intratumor accumulation of FA-
targeted liposomes versus untargeted ones [56], LNDF resulted however
more eﬀective than LND.
Interestingly, LNDF-treated tumors subjected to a chemotherapy
regimen that mimics the regimes followed by patients (i.e. treatment
cycles followed by “drug holiday” period) did not acquire secondary
resistance to the drug. Although we cannot exclude that resistance to
LNDF may occur at later time-points, we hypothesize that - at least
during the period of the study - the presence of NO-releasing group,
which is at the same time a component of ND and a MDR-reversing tool,
preserves the chemosensitivity to our formulation.
In all the experimental settings, the liposomal formulations of ND
had a cardiovascular safety proﬁle superior to Dox and comparable to
Caelyx®. The post-mortem analysis of Dox content in tumors and organs
indicated that LNDF had the highest tumor vs healthy tissues ratio ac-
cumulation and that the residual amount of Dox found in liver, heart,
kidneys and heart in mice treated with this formulation was likely too
low to induce detectable organ toxicity. LND and ND granted a lower
intra-tumor accumulation, but they had a safe proﬁle in terms of
systemic toxicity. As expected, Caelyx® had the lowest intra-cardiac
accumulation; on the other hand, its low intra-tumor accumulation
made it ineﬀective in reducing tumor growth. The residual Dox found
in tumors and organs of animals treated with LNDF 2 weeks after the
last treatment was lower than the amount found 1 week after the last
treatment, suggesting that LNDF granted an eﬀective and progressive
clearance of the drug. Overall, these data further enforce the possibility
of a future use of LNDF in clinical settings. Since our priority was to
achieve a signiﬁcant reduction of tumor growth in a model highly re-
fractory to free Dox and Caelyx®, we focused on this aspect in the
present work. We did not plan at ﬁrst a pharmacokinetic study of LNDF,
hence we cannot predict a half-life for LNDF. We will perform such
experiments in next future including either healthy mice and mice
bearing diﬀerent tumor types, given the variability in pharmacokinetic
behavior that diﬀerent tumors may produce on the same receptor-tar-
geted liposomal formulation [57]. This step is necessary for the further
preclinical development of LNDF.
In conclusion, in this work, we synthesized and validated an in-
novative folate-targeted liposomal formulation eﬀective against Pgp-
positive/Dox-resistant tumors. The novelty of our formulation relies on
the combination of: 1) a multi-target Dox-derivative that has been
speciﬁcally conceived to inhibit Pgp-eﬄux and to induce cell death of
drug-resistant cells by the simultaneous activation of independent
pathways; 2) an active targeted liposomal formulation decorated with
folate with the aim to increase the tumor selectivity and, consequently,
improve the therapeutic outcome.
In preclinical models of Pgp-resistant breast tumors, our formula-
tion has revealed superior eﬃcacy to Dox and Caelyx®, and a cardio-
toxicological proﬁle similar to Caelyx®. Over the last 20 years, Caelyx®
has represented the greatest improvement in the ﬁeld of anthracyclines,
thanks to its reduced cardiotoxicity. On the other hand, Caelyx® has not
demonstrated a superior anti-tumor eﬃcacy than Dox in chemoresistant
breast cancer patients [14]. Our formulation represents a step forward
in improving the treatment of FAR-positive/Pgp-positive breast tumors.
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